INM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InMed Pharmaceuticals Inc (INM) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is declining, there are no positive trading signals, and no significant catalysts or news to drive growth. Given the lack of positive momentum and weak financials, holding off on investing in this stock is advisable.
The MACD is slightly positive but contracting, RSI is neutral at 50.851, and moving averages are converging, indicating no clear trend. The stock is trading close to its R1 resistance level of 0.72, but there is no strong upward momentum.
NULL. No recent news, trading trends, or influential figure activity to support a positive outlook.
Declining financial performance with significant YoY drops in revenue (-26.22%), net income (-21.23%), EPS (-85.99%), and gross margin (-49.65%). Additionally, no recent congress trading data or hedge fund activity indicates a lack of institutional interest.
In Q2 2026, revenue dropped to $820,188 (-26.22% YoY), net income dropped to -$2,028,223 (-21.23% YoY), EPS dropped to -0.51 (-85.99% YoY), and gross margin dropped to 15.97% (-49.65% YoY). The company's financials are in decline across key metrics.
No analyst rating or price target changes available for the stock.
